Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
about
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusDapagliflozin for type 2 diabetes mellitusEfficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysisCanagliflozin Treatment in Patients with Type 2 Diabetes MellitusEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusIncretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart diseaseRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionRole of anti-diabetic drugs as therapeutic agents in Alzheimer's diseaseRole of the intestinal bile acid transporters in bile acid and drug dispositionProximal nephronEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.Isolation and characterization of a primary proximal tubular epithelial cell model from human kidney by CD10/CD13 double labelingAdverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsPharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus.Is caveolin involved in normal proximal tubule function? Presence in model PT systems but absence in situ.The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study.Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patientA fluorescence method for measurement of glucose transport in kidney cellsCurrent therapies and emerging drugs in the pipeline for type 2 diabetes.De novo expression of sodium-glucose cotransporter SGLT2 in Bowman's capsule coincides with replacement of parietal epithelial cell layer with proximal tubule-like epithelium.Proximal tubule function and response to acidosis.Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.The Sweet Pee model for Sglt2 mutationManagement of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Dapagliflozin for the treatment of type 2 diabetes: a review of the literatureRenal cells express different forms of vimentin: the independent expression alteration of these forms is important in cell resistance to osmotic stress and apoptosis.Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 DiabetesGlucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesPresent and Prospective Pharmacotherapy for the Management of Patients with Type 2 DiabetesEfficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials.Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.A novel SGLT is expressed in the human kidney.Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
P2860
Q21195757-10FCDCA3-EC98-42F3-87FA-4BED1779C74BQ24234557-8D486281-F77A-4DB0-861F-B5EBB30CE1CFQ26773558-7F607F43-E285-4D93-810C-81231CE1D851Q26777529-EA9FE0F2-14BC-4148-ADB7-784B0614492CQ26782225-2FD09EE8-E6E9-480E-9DAE-2236BF64E1C6Q26784211-A4262C00-D27D-46BB-AAFD-FC901C1B7C46Q27027105-4DCFE515-C05E-4835-B2DA-7D2DD4AA68FCQ28083039-EEAB33D6-9658-4747-A20F-615505F4F9DDQ28299162-3DBA68C1-48F0-40F2-9DA4-D47155AA7187Q28388052-E9F9C6DF-F4C2-4A8D-9E00-3A9DBE718357Q28732080-FC769BBF-CE6E-4E4D-B7D4-3C231C0CFAADQ30426407-6DF501D6-111C-4C1F-A912-F08E1C064604Q30903369-1C130618-8285-4573-886D-1DE81B67C189Q31121258-CB7896AC-7FA3-4292-8EF6-91515A8BD7D7Q33567077-603052CE-1845-40CB-847F-8E23C7FA9164Q33607764-247F682F-E8F6-46C8-9AB9-35396D10790EQ33730072-5707D056-BF1B-4DB5-874B-AF97EB1AF1FDQ33732583-0034341C-4E4B-49C7-B5AD-A28F90E285D1Q33759570-E5CF55D6-5C14-4876-A606-3F707D284239Q33878898-68A2594E-2C4F-4ED8-8440-6945B7AD6D06Q33928941-47213776-0837-4B31-A525-0FD63CDD2CD3Q33983846-094A83EA-3E09-4292-86E0-69B7761D8B7DQ34124765-DDFF05F0-65E0-4368-92C1-AD4E6623923BQ34227891-21D8BA55-9538-4909-A455-3B48FC166B00Q34264365-BB42507D-313D-490B-AE1C-31F908ABD68CQ34315521-AD54926C-C6FF-43A9-BB82-2B1E392C3694Q34457273-24034C76-5C85-47BD-B470-7A9B94960A48Q34457919-57AC6212-0D19-4456-986C-E1D09863C39AQ34710819-40264F29-D449-498F-B47A-542A52F24FECQ34847839-5A129538-F326-432A-A4E2-FC3207735B52Q35111563-B859C007-E72B-4F37-8A9D-400D48EB09FBQ35179843-ECB3A909-1C85-4577-B444-F9B935EFCE3CQ35214420-2C814098-CE34-40E0-BA3B-4483DDAC231BQ35669990-C756AC30-7D1D-46F0-BF47-403432C1230AQ35780861-79006961-1E84-4725-A331-13926C013D95Q35909303-65FD6C68-8CC3-4630-853F-DD43D472C2CFQ36058592-C5D3E7D4-75C4-4C04-830E-A1643AF64C28Q36232787-C0E2CBC2-75A9-49A6-93BE-D709699F92ACQ36706015-BF9865C7-DA0A-4BC5-A9CB-A80E822CD30CQ36997767-35056A4B-0F4F-4199-AD0B-0C91B04491FD
P2860
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal sodium-glucose transport ...... tential clinical implications.
@en
Renal sodium-glucose transport ...... tential clinical implications.
@nl
type
label
Renal sodium-glucose transport ...... tential clinical implications.
@en
Renal sodium-glucose transport ...... tential clinical implications.
@nl
prefLabel
Renal sodium-glucose transport ...... tential clinical implications.
@en
Renal sodium-glucose transport ...... tential clinical implications.
@nl
P2093
P356
P1433
P1476
Renal sodium-glucose transport ...... tential clinical implications.
@en
P2093
Ernest M Wright
George L Bakris
Kumar Sharma
Vivian A Fonseca
P2888
P304
P356
10.1038/KI.2009.87
P407
P577
2009-04-08T00:00:00Z
P5875
P6179
1051402716